CARsgen publishes 2025 annual report, posts RMB 125.7 million revenue

  • CARsgen annual report for 2025 flagged a shift into value realization, led by stronger commercialization of BCMA CAR-T zevorcabtagene autoleucel.
  • Huadong Medicine placed 218 confirmed orders for zevor-cel during 2025.
  • Claudin18.2 CAR-T satricabtagene autoleucel entered China NDA review in June 2025, with approval expected in first half of 2026.
  • Strategy pivot accelerated toward off-the-shelf allogeneic CAR-T, with CT0596 and CT1190B positioned for IND clearance and Phase Ib trial starts in 2026 in China.
  • Manufacturing footprint expanded in Shanghai, with a new Jinshan commercial base planned under a project capped at RMB 370 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260410-12102280), on April 10, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.